Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis.
Thrombocytosis is a common paraneoplastic syndrome in patients with lung cancer. However, complications associated with malignancy-related thrombocytosis, including thrombosis and hemorrhage, have rarely been reported. In this case, we describe a 57-year-old man with unresectable adenocarcinoma of the lung who presented with a platelet count over 100 × 10(4)/mm(3). In addition, deep venous thrombosis of the left femoral vein was found during admission. The circumference of the left lower leg and platelet count progressed during the period without chemotherapy and anticoagulants; however, with the addition of anagrelide they improved. We provided an adjuvant therapy with platelet-lowering therapy to treat cancer-induced thrombocytosis during the period without chemotherapy.
Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Yu-Guang
YG
Chen
Chih-Sheng
CS
Lin
Chih-Hao
CH
Shen
Chih-Feng
CF
Chian
D000230:Adenocarcinoma / Q000150:complications* / Q000188:drug therapy; D000077192:Adenocarcinoma of Lung; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005268:Femoral Vein; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count; D011799:Quinazolines / Q000627:therapeutic use*; D013922:Thrombocytosis / Q000188:drug therapy* / Q000209:etiology
D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide